Ask AI
CDH6 ADCs
CDH6-Targeting Antibody–Drug Conjugates in Ovarian Cancer: A Promising Treatment Approach

Released: November 05, 2025

Activity

Progress
1
Course Completed

In this episode, Kathleen N. Moore, MD, MS, FASCO, and Isabelle Ray-Coquard, MD, PhD, discuss the emerging role of CDH6-targeting antibody–drug conjugates (ADCs) for ovarian cancer, including:

  • Results of the phase I trial of raludotatug deruxtecan (R-DXd) in ovarian cancer
  • Results of the phase II REJOICE-Ovarian01 study in patients with platinum-resistant disease
  • How R-DXd may be incorporated into the treatment paradigm
  • Other investigational CDH6-targeting ADCs: CUSP06, SIM0505